{
    "clinical_study": {
        "@rank": "72205", 
        "arm_group": [
            {
                "arm_group_label": "ETI-204", 
                "arm_group_type": "Experimental", 
                "description": "Intravenously (IV), repeat dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenously (IV), repeat dose"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerability of repeat administration (two doses) of intravenous\n      (IV). To evaluate the pharmacokinetics and immunogenicity of ETI-204 after repeat IV\n      administration."
        }, 
        "brief_title": "Safety, Tolerability and PK of Repeat Administration of IV ETI-204", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Inhalational Anthrax", 
        "condition_browse": {
            "mesh_term": "Anthrax"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Females or males \u2265 18 years of age\n\n          2. All females, regardless of childbearing potential, must have a negative serum beta\n             human chorionic gonadotropin (\u03b2-hCG)  pregnancy test at Screening and Day -1\n\n          3. Females of childbearing potential (i.e., not postmenopausal or surgically sterile)\n             must agree to practice abstinence or to use a medically accepted method of\n             contraception from the time of Screening through 30 days after the final study visit.\n             Acceptable methods of contraception include diaphragm with spermicide; sponge with\n             spermicide; condom with spermicide; or intrauterine device with condom or spermicide.\n             The following contraceptive methods are acceptable only when used with a condom and\n             spermicide: birth control pills, birth control patches, vaginal ring, hormone under\n             the skin, or hormone injections\n\n          4. Postmenopausal females, defined as females who have had amenorrhea for at least 12\n             months either naturally or following cessation of all exogenous hormonal treatments,\n             and have a follicle-stimulating hormone (FSH) level of > 40 mIU/mL at Screening\n\n          5. Females who have undergone surgical sterilization, including hysterectomy, bilateral\n             oophorectomy, bilateral salpingectomy, tubal ligation, or tubal essure\n\n          6. Males must agree to practice abstinence or use a condom with spermicide and refrain\n             from sperm donation during the study and for 30 days after the final study visit\n\n          7. Provide written informed consent\n\n          8. Willing to comply with study restrictions\n\n        Exclusion Criteria:\n\n          1. Pregnant or lactating woman\n\n          2. Clinically significant comorbidity that would interfere with completion of the study\n             procedures or objectives or compromise the subject's safety\n\n          3. Seated systolic blood pressure (BP) \u2265 150 mmHg or \u2264 90 mmHg or diastolic BP \u2265 95 mmHg\n\n          4. Use of H1 receptor antagonists (i.e. antihistamines) within 5 days prior to Day 1\n\n          5. Evidence of drug or alcohol abuse as determined by the Investigator within 6 months\n             of Day 1\n\n          6. Positive test result for drugs of abuse (with the exception of medically prescribed\n             drugs) at Screening or on Day -1\n\n          7. Positive test for alcohol at Screening; exclusion is at the Investigator's\n             discretion; subjects who test positive for alcohol at Day -1 are excluded from the\n             study\n\n          8. Treatment with an investigational agent within 30 days or five half-lives of the\n             investigational agent at Day 1 (whichever is longer)\n\n          9. Congenital or acquired immunodeficiency syndrome\n\n         10. Prior solid organ or bone marrow transplant\n\n         11. Positive test for Hepatitis B (surface antigen), Hepatitis C, or human\n             immunodeficiency virus (HIV) at Screening\n\n         12. History of prior treatment for anthrax exposure or prior anthrax infection\n\n         13. Prior immunization with any approved or investigational anthrax vaccine or prior\n             treatment with an approved or investigational anthrax treatment (i.e., ETI-204,\n             raxibacumab, or anthrax immune globulin)\n\n         14. Military personnel deployed in 1990 or after, unless the subject can provide\n             documentation demonstrating they have not previously received any approved or\n             investigational anthrax vaccine\n\n         15. Use of systemic steroids, immunosuppressive agents, anticoagulants, or\n             anti-arrhythmics within 1 year prior to Day 1. A single short course (i.e., less than\n             14 days) of systemic steroid therapy is allowed provided it concluded more than 6\n             months prior to Day 1\n\n         16. Donation or loss of > 500 mL of blood within 30 days or plasma within 7 days of Day 1\n\n         17. Prior stroke, epilepsy, relapsing or degenerative central nervous system disease, or\n             relapsing or degenerative ocular disease\n\n         18. Myocardial infarction or acute coronary syndrome in the past 5 years, active angina\n             pectoris, or heart failure (New York Heart Association scale > 1)\n\n         19. History of chronic liver disease\n\n         20. Calculated creatinine clearance (CrCl) of < 30 mL/min using the Cockcroft-Gault\n             equation (see Section 5.1)\n\n         21. Any clinically significant abnormality, in the Investigator's opinion, on\n             electrocardiogram (ECG) or clinical laboratory tests (hematology, clinical chemistry,\n             or urinalysis) at Screening; Out of range results may be repeated to confirm.\n\n         22. History of allergic or hypersensitivity reactions to other therapeutic antibodies or\n             immunoglobulins\n\n         23. History of any malignant neoplasm within the last 5 years, with the exception of\n             adequately treated, localized or in situ non-melanoma carcinoma of the skin (e.g.,\n             basal cell carcinoma) or the cervix\n\n         24. Subjects who, in the opinion of the Investigator, are not suitable candidates for\n             enrollment or who may not comply with the requirements of the study\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932242", 
            "org_study_id": "AH109"
        }, 
        "intervention": [
            {
                "arm_group_label": "ETI-204", 
                "description": "Monoclonal Antibody", 
                "intervention_name": "ETI-204", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo comparator", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological", 
                "other_name": "Placebo comparator"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66211"
                    }, 
                    "name": "Quintiles"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "DaVita"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Repeat Administration of Intravenous ETI-204 in Adult Volunteers", 
        "overall_official": {
            "affiliation": "Quintiles", 
            "last_name": "David Mathews, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be assessed by collecting and monitoring vital signs, laboratory tests, ECGs, physical examinations, skin assessments, infusion site assessments and AEs.", 
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "220 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932242"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "All PK parameters will be descriptively analyzed by treatment/dosing group for the PK analysis population.", 
                "measure": "Pharmacokinetics (PK) analysis", 
                "safety_issue": "No", 
                "time_frame": "220 days"
            }, 
            {
                "description": "Anti-ETI-204 analyses at each time point will be listed by subject and summarized as appropriate.", 
                "measure": "Anti-ETI-204 Antibody", 
                "safety_issue": "No", 
                "time_frame": "220 days"
            }
        ], 
        "source": "Elusys Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elusys Therapeutics", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}